A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) In BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, and High Grade Serous Ovarian Cancer

Trial Profile

A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) In BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, and High Grade Serous Ovarian Cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Apr 2018

At a glance

  • Drugs Prexasertib (Primary)
  • Indications Breast cancer; Ovarian cancer
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 04 Apr 2018 Planned End Date changed from 3 Jun 2019 to 30 Jun 2020.
    • 04 Apr 2018 Planned primary completion date changed from 4 Jun 2018 to 28 Jun 2019.
    • 17 Jan 2018 Results of the final analysis of the cohort of patients with BRCA wild-type high-grade serous ovarian carcinoma (n=28) published in the Lancet Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top